Bispecific antibody · Antagonist of epidermal growth factor receptor (EGFR) and leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) · developed by Genmab
Petosemtamab is an IgG1 bispecific antibody that binds both EGFR and LGR5, inhibiting signaling through both receptors and thereby tumor cell proliferation. It is being studied in solid tumors including colorectal cancer, gastric and gastroesophageal-junction cancer, non-small cell lung cancer, and head and neck squamous cell carcinoma, alone or in combination with chemotherapy or pembrolizumab.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06525220 | Phase 3 | Head and Neck Squamous Cell Carcinoma | Active not recruiting | GMAB |
| NCT03526835 | Phase 1/2 | Advanced/Metastatic Solid Tumors | Recruiting | GMAB |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced/Metastatic Solid TumorsColorectal CancerEsophageal CancerGastric CancerGastroesophageal-junction CancerHead and Neck Squamous Cell CarcinomaHNSCCNSCLC
Updated Nov 8, 2026. Something wrong or missing? Report it on the GMAB page.
See GMAB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
GMAB catalysts and pipeline →